April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
The Addition Of Benzalkonium Chloride To Moxifloxacin Confers Anti-acanthamoebal Activity In An In Vitro Model
Author Affiliations & Notes
  • Elmer Y. Tu
    Ophthalmology, University of Illinois at Chicago, Glenview, Illinois
  • Megan E. Shoff
    Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland
  • Charlotte E. Joslin
    Ophthalmology/Visual Sciences, University Illinois at Chicago, Chicago, Illinois
    School of Public Health, University of Illinois at Chicago, Chicago, Illinois
  • Footnotes
    Commercial Relationships  Elmer Y. Tu, Alcon International (R); Megan E. Shoff, None; Charlotte E. Joslin, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5830. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elmer Y. Tu, Megan E. Shoff, Charlotte E. Joslin; The Addition Of Benzalkonium Chloride To Moxifloxacin Confers Anti-acanthamoebal Activity In An In Vitro Model. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5830.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Purpose: To determine the activity of moxifloxacin alone and moxifloxacin supplemented with lower concentrations of benzalkonium chloride (BAK) against acanthamoeba in an established in vitro model.

Methods: : Methods: Trophozoites cultures of Acanthamoeba castellanii were incubated in non-nutrient amoeba saline + Enterobacter aerogenes. Three replicates of four solutions, moxifloxacin 0.5% alone, moxifloxacin 0.5% supplemented with BAK to achieve final concentrations of 0.001% and 0.003% and the unsupplemented amoeba saline acting as a control. Samples were taken at 30 minutes, and 1.5, 2.5, 4, 5.5, and 7 hours after exposureand immediately quanified. Amoeba counts were estimated using the most probable number method (MPN), as previously described, utilizing serial dilutions.

Results: : Results: MPN estimates showed no signficant reduction in the number of acanthamoeba organisms at any time point for moxifloxacin alone when compared to the control. Moxifloxacin + 0.001% BAK showed variable, modest reductions at all time points. Moxifloxacin + 0.003% BAK resulted in profound reductions ranging from 1.8 up to 3.9 log units versus control at all time points.

Conclusions: : Conclusions: Moxifloxacin alone did not demonstrate any significant effect on acanthamoeba trophozoites in this established in vitro model. The addition of small concentrations of BAK, below that seen in many commercial eyedrop formulations can result in a significant and profound reduction in the number of acanthamoebal organisms with exposures of as little as 30 minutes. The contribution and exclusion of preservatives like BAK will need to be accounted for in the assessment, research and development of present and future ophthalmic medications and contact lens disinfection systems.

Keywords: Acanthamoeba • microbial pathogenesis: experimental studies • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.